Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 3 minute read Pharma Industry News Pfizer’s Phase 3 clinical trial of XELJANZ in ankylosing spondylitis: A breakthrough in treatment Pfizer has announced the successful completion of a Phase 3 clinical trial for its drug XELJANZ (tofacitinib) in… bypharmanewsdailyNovember 8, 2020
